Tag Archives: Pfizer
By Guest Blogger | Published: September 21, 2012
By Amy Ritter. Ten biopharmaceutical companies announced the formation of a nonprofit organization called TransCelerate BioPharma, the mission of which is to accelerate the development of new medicines by identifying and solving common drug development challenges.
By Julian Upton | Published: February 2, 2012
UK Waits for AZ Job Cut Breakdown As this blog was posted, AstraZeneca was still keeping the world in suspense as to a further breakdown of its announced 7,300 job cuts. The company’s UK staff assembled for a meeting at 10 am, but as of lunchtime there was still no confirmation of the actual numbers , [...]
By Guest Blogger | Published: September 21, 2011
Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will best be [...]
By Ben Comer | Published: August 16, 2011
Three of the twelve appointees to the Joint Select Committee on Deficit Reduction (aka Super Committee) received over $300,000 in campaign contributions from pharmaceutical companies, according to Center for Responsive Politics data, and a MapLight analysis.
By William Looney | Published: June 29, 2011
Pfizer’s crizotinib development program combined organization, art, and science— and a large dose of unforeseen risk. The path to commercializing a breakthrough discovery is rarely a linear process. The orderly rationale of the scientific method is often overtaken by the random artistry of passion, personality, business culture, and sheer luck. Each plays a [...]